Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InMed Pharmaceuticals Inc. (INM : NSDQ)

• Company Description    InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $2.82 Daily Weekly Monthly 20 Day Moving Average: 5,690,050 shares Shares Outstanding: 1.21 (millions) Market Capitalization: $3.40 (millions) Beta: 0.30 52 Week High: $9.38 52 Week Low: $1.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.83% 0.91% 12 Week 3.82% -12.67% Year To Date -40.51% -44.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Suite 1445 - 885 West Georgia Street - VANCOUVER,A1 V6C 3E8 CAN ph: 604-669-7207 fax: - ir@inmedpharma.com http://www.inmedpharma.com

• General Corporate Information    Officers Eric A. Adams - Chief Executive Officer; President and Director Andrew Hull - Chairman and Director Netta Jagpal - Interim Chief Financial Officer Janet Grove - Director Bryan Baldasare - Director Peer Information InMed Pharmaceuticals Inc. (GSAC) InMed Pharmaceuticals Inc. (CASI) InMed Pharmaceuticals Inc. (ALCD.) InMed Pharmaceuticals Inc. (OMNN) InMed Pharmaceuticals Inc. (CGPI.) InMed Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 457637700 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/25 Next Expected EPS Date: 09/26/25 Share - Related Items Shares Outstanding: 1.21 Most Recent Split Date: 11.00 (0.05:1) Beta: 0.30 Market Capitalization: $3.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/26/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.48 Price/Cash Flow: - Price / Sales: 0.69 EPS Growth vs. Year Ago Period: 46.11% vs. Previous Quarter: 46.70% Sales Growth vs. Year Ago Period: 7.59% vs. Previous Quarter: 13.49% ROE 06/30/25 - - 03/31/25 - -107.93 12/31/24 - -90.74 ROA 06/30/25 - - 03/31/25 - -82.97 12/31/24 - -71.70 Current Ratio 06/30/25 - - 03/31/25 - 3.49 12/31/24 - 3.05 Quick Ratio 06/30/25 - - 03/31/25 - 3.04 12/31/24 - 2.44 Operating Margin 06/30/25 - - 03/31/25 - -168.87 12/31/24 - -163.75 Net Margin 06/30/25 - - 03/31/25 - -168.87 12/31/24 - -163.75 Pre-Tax Margin 06/30/25 - - 03/31/25 - -168.71 12/31/24 - -163.58 Book Value 06/30/25 - - 03/31/25 - 5.82 12/31/24 - 8.54 Inventory Turnover 06/30/25 - - 03/31/25 - 3.04 12/31/24 - 2.62 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.06 12/31/24 - 0.09 Debt-to-Capital 06/30/25 - - 03/31/25 - 5.63 12/31/24 - 7.88

Powered by Zacks Investment Research ©